Her-2 positive and TNBC patients receiving neoadjuvant chemotherapy are associated with a high pathological complete response rate – results from real-world outcomes in a multidisciplinary setting. (April 2021) - Rapoport, B.L.; Smit, T.; Heyman, L.; Benn, C.A.; Nayler, S.